CVS Health Corporation (CVS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$80.69
Price Target
$95.20
Target Range
$90.00 — $101.00
Analyst Rating
Buy
Forward P/E11.3x
Trailing P/E58.1x
Forward PEG—
Implied Growth+417.4%
Median Target$94.50
Analyst Spread11.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$90
+11.5%
Consensus
$95
+18.0%
Bull Case
$101
+25.2%
Valuation Model TargetsConfidence: 68/100
Bear$164
Base$305
Bull$643
CVS Price Target Analysis
Updated May 6, 2026As of May 6, 2026, CVS Health Corporation (CVS) has a Wall Street consensus price target of $95.20, based on estimates from 41 covering analysts. With the stock currently trading at $80.69, this represents a potential upside of +18.0%. The company has a market capitalization of $102.56B.
Analyst price targets range from a low of $90.00 to a high of $101.00, representing a 12% spread in expectations. The median target of $94.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 35 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CVS trades at a trailing P/E of 58.1x and forward P/E of 11.3x. Analysts expect EPS to grow +417.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $304.76, with bear and bull scenarios of $163.97 and $643.08 respectively. Model confidence stands at 68/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+13.9%
Avg Forward P/E18.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 UNHUnitedHealth Group Incorporated | $330.3B | $363.87 | $385.43 | +5.9% | Buy | 19.9x | 52 |
 CICigna Corporation | $72.7B | $275.66 | $328.00 | +19.0% | Buy | 9.1x | 39 |
 ELVElevance Health Inc. | $80.1B | $369.07 | $382.38 | +3.6% | Buy | 13.8x | 37 |
 HUMHumana Inc. | $28.8B | $239.53 | $246.00 | +2.7% | Hold | 26.8x | 44 |
 MCKMcKesson Corporation | $98.1B | $801.01 | $1006.50 | +25.7% | Buy | 20.5x | 31 |
 CAHCardinal Health, Inc. | $46.4B | $197.00 | $249.67 | +26.7% | Buy | 19.1x | 33 |
 LLYEli Lilly and Company | $933.7B | $988.19 | $1258.47 | +27.4% | Buy | 28.6x | 45 |
 PFEPfizer Inc. | $150.4B | $26.44 | $27.27 | +3.1% | Hold | 8.9x | 39 |
 JNJJohnson & Johnson | $543.6B | $225.59 | $249.27 | +10.5% | Buy | 19.5x | 40 |
 MRKMerck & Co., Inc. | $279.5B | $113.16 | $129.31 | +14.3% | Buy | 22.1x | 37 |
Upside Potential Comparison
LLYCAHMCKCIMRKJNJUNHELVFull CVS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See CVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CVS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCVS — Frequently Asked Questions
Quick answers to the most common questions about buying CVS stock.
What is the CVS stock price target for 2026?
CVS Health Corporation (CVS) has a consensus 12-month price target of $95.2, implying 18.0% upside from $80.69. The 41 analysts covering CVS see moderate appreciation potential.
Is CVS a buy, sell, or hold?
CVS has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 35 Buy/Strong Buy ratings. The consensus 12-month price target of $95.2 implies 18.0% upside from current levels.
Is CVS stock overvalued or undervalued?
With a forward P/E of 11.2651x, CVS trades at a relatively low valuation. The consensus target of $95.2 implies 18.0% appreciation, suggesting meaningful undervaluation.
How high can CVS stock go?
The most bullish Wall Street analyst has a price target of $101 for CVS, while the most conservative target is $90. The consensus of $95.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $643 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover CVS stock?
CVS is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 2 have Strong Buy ratings, 33 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CVS stock forecast?
The 12-month CVS stock forecast based on 41 Wall Street analysts shows a consensus price target of $95.2, with estimates ranging from $90 (bear case) to $101 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $305, with bear/bull scenarios of $164/$643.
What is CVS's fair value based on fundamentals?
Our quantitative valuation model calculates CVS's fair value at $305 (base case), with a bear case of $164 and bull case of $643. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 68/100.
What is CVS's forward P/E ratio?
CVS trades at a forward P/E ratio of 11.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 58.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CVS stock?
Wall Street analysts are optimistic on CVS, with a "Buy" consensus rating and $95.2 price target (18.0% upside). 35 of 41 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CVS price targets vary so much?
CVS analyst price targets range from $90 to $101, a 12% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $95.2 consensus represents the middle ground. Our model's $164-$643 range provides an independent fundamental perspective.